April 4, 2012
BIND Biosciences Presents Clinical Data on BIND-014 Promising Anti-tumor Effects in Patients with Advanced or Metastatic Cancers

 
January 27, 2012
Daniel Bertholet of Endeavour Vision speaks at SECA event

 
December 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
October 27, 2011
BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline

 
September 30, 2011
Symetis’ ACURATE TA™ Aortic Bioprosthesis Receives CE Mark Certification on Sept. 30th 2011

 
May 18, 2011
Symetis reports on its trans-apical ACURATE TA™ clinical

 
May 4, 2011
Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

 
April 28, 2011
Molecular Partners reports positive results from its first clinical studies

 
April 6, 2011
BIND Biosciences Receives 2011 Edison Award

 
February 23, 2011
BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row

 
February 15, 2011
Nfocus Neuromedical, Inc. Luna™ Aneurysm Embolization System Receives CE Mark

 
February 11, 2011
BIND Biosciences featured in the London Times

 
February 8, 2011
Molecular Partners enters into a Strategic Research Collaboration and Option Agreement with Janssen Biotech, Inc. in Immunology to Develop Multispecific DARPins®

 
January 7, 2011
BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014

 
January 4, 2011
PneumRx, Inc. Raises $33 Million in Capital

 
April 13, 2010
CeQur SA names Robert O'Holla EVP for Regulatory Affairs

 
Data Indicative of Targeting Ability of BIND-014 for High Tumor Drug Concentration

Late-Breaker Data Presented at the AACR 2012 Annual Meeting for BIND-014, Lead Candidate from BIND’s Accurin Platform for Targeted and Programmable Nanomedicines


Cambridge, MA, April 4, 2012 –BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called AccurinsTM, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting. BIND presented data from the ongoing Phase 1 clinical study of BIND-014, its targeted docetaxel Accurin, in patients with solid tumors that strongly translated from preclinical data, demonstrated safety and tolerability, and showed evidence of anti-tumor activity with six of 17 pat ...

more...
© Endeavour Vision SA 2006-2012 Terms & Conditions